Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial-Reference-Cited by-同舟云学术

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Published:2022-03 Issue:3 Volume:10 Page:193-206
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Kadowaki Takashi,Isendahl Joakim,Khalid Usman,Lee Sang Yeoup,Nishida Tomoyuki,Ogawa Wataru,Tobe Kazuyuki,Yamauchi Toshimasa,Lim Soo

Funder

Novo Nordisk

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. Guidelines for the management of obesity disease,2016

2. 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea;Seo;J Obes Metab Syndr,2019

3. Criteria and classification of obesity in Japan and Asia-Oceania;Kanazawa;World Rev Nutr Diet,2005

4. Association between obesity and cardiovascular outcomes: a systematic review and meta-analysis of Mendelian randomization studies;Riaz;JAMA Netw Open,2018

5. Quantitative association between body mass index and the risk of cancer: a global meta-analysis of prospective cohort studies;Fang;Int J Cancer,2018

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments;Sleep Medicine Reviews;2024-12

2. AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys;Molecular Metabolism;2024-10

3. Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement;Medicine & Science in Sports & Exercise;2024-10

4. Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations;Cureus;2024-09-06

5. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-09-03